Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition.

Federica IannelliMaria Serena RocaRita LombardiChiara CiardielloLaura GrumettiSimona De RienzoTania MocciaCarlo VitaglianoAngela SoriceSusan CostantiniMaria Rita MiloneBiagio PucciAlessandra LeoneElena Di GennaroRita ManciniGennaro CilibertoFrancesca BruzzeseAlfredo Budillon

Published in: Journal of experimental & clinical cancer research : CR (2020)

Overall, mCRPC progression and therapeutic resistance driven by CSCs via YAP, can be tackled by the combined repurposing of two generic and safe drugs, an approach that warrants further clinical development in this disease.

Keyphrases

prostate cancer
cancer stem cells
radical prostatectomy
cancer therapy
locally advanced
squamous cell carcinoma
drug delivery
radiation therapy
drug induced
rectal cancer